Letters Section Editor: Robert M. Golub,
MD, Senior Editor.
To the Editor: Dr Valgimigli and colleagues1 evaluated the clinical and angiographic effects of
single high-dose bolus tirofiban plus sirolimus-eluting stenting vs abciximab
plus bare-metal stenting. In this study, a baseline Thrombolysis in Myocardial
Infarction grade of 0 to 1 was present in more than 70% of patients. A postprocedure
grade 3 was achieved in more than 90% of patients, but the myocardial blush
grade after reperfusion, one of the most important angiographic indices of
myocardial reperfusion and predictors of left ventricular recovery,2 was not mentioned. Also, the authors did not specify
if any intracoronary thrombectomy device, balloon predilatation, or intracoronary
vasodilators were used.
De Luca L, Sardella G. Tirofiban Plus Sirolimus-Eluting Stent vs Abciximab Plus Bare-Metal
Stent. JAMA. 2005;294(13):1616–1618. doi:10.1001/jama.294.13.1617-a
Browse and subscribe to JAMA Network podcasts!
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: